The Epinephrine Auto-Injectors Market is poised for a surge, driven by a growing emphasis on allergy awareness and preparedness. According to a recent industry report by Future Market Insights (FMI), ...
Dublin, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The "Epinephrine Auto-Injection Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Epinephrine ...
Dublin, Nov. 10, 2020 (GLOBE NEWSWIRE) -- The "Epinephrine Auto-Injector Market by Age group, Dosage, by End-user, and Geography - Global Drivers, Restraints, Opportunities, Trends, and Forecast up to ...
According to Arizton’s latest research report, the epinephrine auto-injector market is growing at a CAGR of 8.82% during 2023-2029. Stay ahead of the curve with Arizton's exclusive subscription plan, ...
The Epinephrine Auto-Injectors Market Sales is expected to expand to US$ 3.2 billion by 2032, up from US$ 2 billion in 2022, with a compound annual growth rate (CAGR) of 4.9% between 2022 and 2032.
MHRA has issued a drug alert for the Emerade adrenaline auto-injector device, as a result of the device’s potential to fail in delivery of the dose due to blockage of the needle. The Medicines and ...
GPs should restrict adrenaline auto-injector prescriptions due to ongoing supply issues, the Department of Health and Social Care has said. The Government alert told GPs that ‘interruptions in the ...
Allergists Dr Andrew Clark and Dr Shuaib Nasser offer tips on who needs one and advice to give patients 1. Any patient who has experienced symptoms of airway narrowing or cardiovascular compromise ...
Allergy patients are being warned of a potential fault with Emerade adrenaline pens. The Medicines and Healthcare products Regulatory Agency (MHRA) said some have blocked needles, so cannot deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback